Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTX Nkarta

Post-Mkt 05-27 18:53:47 EDT

3.19

+0.13

+4.25%

盘后3.18

-0.01-0.31%

18:30 EDT

High3.34	Low3.03	Vol600.08K
Open3.04	D1 Closing3.06	Amplitude10.25%
Mkt Cap228.23M	Tradable Cap167.51M	Total Shares71.55M
T/O1.94M	T/O Rate1.14%	Tradable Shares52.51M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTX","market":"US","secType":"STK","nameCN":"Nkarta","latestPrice":3.19,"timestamp":1779912000000,"preClose":3.06,"halted":0,"volume":600075,"hourTrading":{"tag":"盘后","latestPrice":3.18,"preClose":3.19,"latestTime":"18:30 EDT","volume":5005,"amount":15955.879939999999,"timestamp":1779921043874,"change":-0.01,"changeRate":-0.003135,"amplitude":0.003135},"delay":0,"changeRate":0.04248366013071892,"floatShares":52510907,"shares":71545358,"eps":-1.34905,"marketStatus":"Post-Mkt","change":0.13,"latestTime":"05-27 18:53:47 EDT","open":3.04,"high":3.3386,"low":3.025,"amount":1943612.321175,"amplitude":0.102484,"askPrice":3.3,"askSize":10,"bidPrice":2.99,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.34905,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1779926400000},"marketStatusCode":4,"adr":0,"listingDate":1594353600000,"exchange":"NASDAQ","adjPreClose":3.06,"postHourTrading":{"tag":"盘后","latestPrice":3.18,"preClose":3.19,"latestTime":"18:30 EDT","volume":5005,"amount":15955.879939999999,"timestamp":1779921043874,"change":-0.01,"changeRate":-0.003135,"amplitude":0.003135},"volumeRatio":1.171051,"impliedVol":1.2245,"impliedVolPercentile":0.8964},"requestUrl":"/m/hq/s/NKTX","defaultTab":"news","newsList":[{"id":"2635808188","title":"Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m","url":"https://stock-news.laohu8.com/highlight/detail?id=2635808188","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635808188?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:13","pubTimestamp":1778843626,"startTime":"0","endTime":"0","summary":"Over the past year, insiders sold US$69k worth of Nkarta, Inc. ( NASDAQ:NKTX ) stock at an average price of US$2.06 per...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktx/nkarta/news/nkarta-insider-stock-sellers-must-be-relieved-as-market-cap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktx/nkarta/news/nkarta-insider-stock-sellers-must-be-relieved-as-market-cap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4505","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635736965","title":"Nkarta (NKTX) Gets a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2635736965","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635736965?lang=en_us&edition=fundamental","pubTime":"2026-05-13 23:15","pubTimestamp":1778685321,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nkarta today and set a price target of $11.00. Willey covers the Healthcare secto...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/nkarta-nktx-gets-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/nkarta-nktx-gets-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","BK4588","BK4581","XLV","BK4505","NKTX","SF","BK4139","BK4585","XBI","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635785293","title":"Nkarta Price Target Maintained With a $11.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2635785293","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635785293?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:55","pubTimestamp":1778669700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 06:55 ET (10:55 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635788051","title":"Nkarta Buy Rating Reaffirmed as NKX019 Autoimmune Trials Advance; $16 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2635788051","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635788051?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:19","pubTimestamp":1778667594,"startTime":"0","endTime":"0","summary":"Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Nkarta, retaining the price target of $16.00. Emily Bodnar has given his Buy rat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/nkarta-buy-rating-reaffirmed-as-nkx019-autoimmune-trials-advance-16-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/nkarta-buy-rating-reaffirmed-as-nkx019-autoimmune-trials-advance-16-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635226535","title":"Nkarta reports Q1 EPS (37c), consensus (37c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635226535","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635226535?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:15","pubTimestamp":1778624115,"startTime":"0","endTime":"0","summary":"“Putting patients first and providing access to care in a familiar setting close to home matters” said Paul Hastings, CEO of Nkarta (NKTX). “In ear...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nkarta-reports-q1-eps-37c-consensus-37c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nkarta-reports-q1-eps-37c-consensus-37c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240708","title":"Nkarta Q1 EPS $(0.37), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240708","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240708?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:33","pubTimestamp":1778618021,"startTime":"0","endTime":"0","summary":"Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which met the analyst consensus estimate. This is a 13.95 percent increase over losses of $(0.43) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52507720/nkarta-q1-eps-0-37-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Nkarta Q1 EPS $(0.37), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635403842","title":"Nkarta Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635403842","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635403842?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:17","pubTimestamp":1778617030,"startTime":"0","endTime":"0","summary":"Nkarta Inc reports results for the quarter ended March 31 - Earnings SummaryNkarta Inc NKTX.OQ reported a quarterly adjusted loss of 37 cents per share for the quarter ended March 31, higher than the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P31M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247245","title":"Nkarta Q1 net loss narrows; cash seen funding to 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247245","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247245?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:11","pubTimestamp":1778616665,"startTime":"0","endTime":"0","summary":"Nkarta Q1 net loss narrows;cash seen funding to 2029OverviewUS biotechnology firm's Q1 net loss was $27.8 mln, basic EPS at -$0.37Cash and investments totaled $266.7 mln, expected to fund operations i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL1N41P1CI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242056","title":"Nkarta Q1 FY26 net loss narrows to $27.8 million; G&A expenses drop to $5.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242056","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242056?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:02","pubTimestamp":1778616162,"startTime":"0","endTime":"0","summary":"Nkarta posted a net loss of $27.8 million, or $0.37 per share, for Q1 2026.R&D expense edged up to $25 million, while G&A expense dropped to $5.9 million.Cash, cash equivalents, restricted cash, and investments fell to $266.7 million as of March 31, with runway expected to fund operations into 2029.Protocol changes agreed with FDA allow outpatient dosing in community settings, add an option to re-dose, remove overnight monitoring requirements, and expand Ntrust-2 to include rheumatoid arthritis.Enrollment continues at the 4 billion-cell dose level across Ntrust-1 and Ntrust-2, with initial clinical data planned for presentation at a medical meeting in 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL8GgHxb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","IE00B64PRP62.GBP","LU2095319765.USD","BK4112","LU0314104364.USD","SG9999014005.SGD","NDAQ","IE00BGHQF748.EUR","BK4139","BK4585","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","NKTX","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","SG9999014021.USD","BK4505","SG9999014039.USD","LU2210150020.SGD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242200","title":"BRIEF-Nkarta Q1 EPS USD -0.37","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242200","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242200?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:01","pubTimestamp":1778616105,"startTime":"0","endTime":"0","summary":"BRIEF-Nkarta Q1 EPS USD -0.37\n\n\nMay 12 (Reuters) - Nkarta Q1 net income USD -27.832 million.\n\nQ1 basic EPS USD -0.37\nQ1 cash & investments USD 266.7 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXCE07AE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635422472","title":"Nkarta Q1 Cash & Investments USD 266.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635422472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635422472?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:01","pubTimestamp":1778616060,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXCE07AE:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","NKTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242065","title":"Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242065","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242065?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:01","pubTimestamp":1778616060,"startTime":"0","endTime":"0","summary":"Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3293350/0/en/Nkarta-Reports-First-Quarter-2026-Financial-Results-and-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","NKTX","CAR","BK4022","BK4139","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629865761","title":"Nkarta announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629865761","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629865761?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:55","pubTimestamp":1776977725,"startTime":"0","endTime":"0","summary":"Nkarta will hold virtual annual stockholder meeting on June 10, 2026.Director elections set for two Class III nominees, Ali Behbahani and Zachary Scheiner, for terms running to 2029 annual meeting.Advisory vote scheduled on named executive officer compensation.Separate advisory vote planned on frequency of future executive pay votes, with board backing annual cadence.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. nkarta Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDLb4LCMf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627291047","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Nkarta (NKTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2627291047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627291047?lang=en_us&edition=fundamental","pubTime":"2026-04-16 18:40","pubTimestamp":1776336035,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB) and Nkarta (NKTX). Biogen (BIIB) In ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-biogen-biib-and-nkarta-nktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-biogen-biib-and-nkarta-nktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIIB","LU0029874061.USD","LU0889565916.HKD","BK4581","BK4585","BK4588","NKTX","LU0234570918.USD","BK4532","IE00B894F039.SGD","LU0128526141.USD","BK4137","LU0320765992.SGD","IE00B19Z9Z06.USD","LU0109394709.USD","BK4533","BK4505","IE00B19Z9P08.USD","LABU","XLV","BK4139","XBI","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627230306","title":"Nkarta announces agreement with FDA on changes to Ntrust-1, Ntrust-2 trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2627230306","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627230306?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:05","pubTimestamp":1776283513,"startTime":"0","endTime":"0","summary":"Nkarta (NKTX) announced that it has reached agreement with the FDA on key changes to the ongoing Ntrust-1 and Ntrust-2 clinical trials. The protoco...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nkarta-announces-agreement-with-fda-on-changes-to-ntrust-1-ntrust-2-trials-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nkarta-announces-agreement-with-fda-on-changes-to-ntrust-1-ntrust-2-trials-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","BK4139","BK4585","NKTX","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237930","title":"Nkarta wins FDA nod for outpatient dosing in NKX019 autoimmune trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237930","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237930?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:01","pubTimestamp":1776283310,"startTime":"0","endTime":"0","summary":"Nkarta reached FDA agreement to amend Ntrust-1 and Ntrust-2 trials to enable outpatient dosing of investigational CAR-NK therapy NKX019, expanding access to community rheumatology centers.Protocol changes cut required post-dose monitoring to 2 hours from 24 hours, reducing patient burden and supporting broader trial-site participation.Trial design now allows optional re-dosing in both studies to support response optimization.Ntrust-2 will add a rheumatoid arthritis cohort once protocol amendments clear FDA submission and IRB review, widening the autoimmune disease focus.Initial data from ongoing dosing at 4 billion cells per dose are expected to be presented at a medical meeting later this year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL3Jt3Rm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4112","LU2210150020.SGD","NDAQ","SG9999014005.SGD","NKTX","IE00BN0W2W23.USD","BK4139","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014039.USD","BK4585","SG9999014021.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4588","BK4505","IE00BGHQF748.EUR","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627376032","title":"Nkarta Inc - Rheumatoid Arthritis Cohort to Be Added to Ntrust-2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2627376032","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627376032?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:01","pubTimestamp":1776283260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA1LQJRL:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTX","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237676","title":"Nkarta Inc - Dosing Continues at 4 Bln Cells per Dose, Data Expected This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237676","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237676?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:01","pubTimestamp":1776283260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA1LQJRL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTX","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237674","title":"Nkarta Inc - FDA Agrees to Redosing Option in Ntrust-1 and Ntrust-2 Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237674?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:01","pubTimestamp":1776283260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA1LQJRL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTX","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237605","title":"Nkarta Inc - FDA Agrees to Outpatient Administration of Nkx019 in Community Settings","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237605?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:01","pubTimestamp":1776283260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA1LQJRL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","NKTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nkartatx.com","stockEarnings":[{"period":"1week","weight":0.1418},{"period":"1month","weight":0.0479},{"period":"3month","weight":0.1815},{"period":"6month","weight":0.6721},{"period":"1year","weight":0.7486},{"period":"ytd","weight":0.6541}],"compareEarnings":[{"period":"1week","weight":0.023},{"period":"1month","weight":0.0513},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.1043},{"period":"1year","weight":0.2961},{"period":"ytd","weight":0.1007}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.051655},{"month":2,"riseRate":0.5,"avgChangeRate":0.038672},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.082697},{"month":4,"riseRate":0.666667,"avgChangeRate":0.177626},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.096282},{"month":6,"riseRate":0.2,"avgChangeRate":-0.109268},{"month":7,"riseRate":1,"avgChangeRate":0.107935},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.06764},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.061634},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.060284},{"month":11,"riseRate":0.5,"avgChangeRate":-0.004483},{"month":12,"riseRate":0.333333,"avgChangeRate":0.310979}],"exchange":"NASDAQ","name":"Nkarta","nameEN":"Nkarta"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nkarta(NKTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nkarta,NKTX,Nkarta股票,Nkarta股票老虎,Nkarta股票老虎国际,Nkarta行情,Nkarta股票行情,Nkarta股价,Nkarta股市,Nkarta股票价格,Nkarta股票交易,Nkarta股票购买,Nkarta股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nkarta(NKTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}